Biotech IPOs Outpace AI Listings in US Market in 2026

The biotechnology sector outperformed AI-related listings in the US IPO market in 2026, delivering remarkable returns. As bankers steadily roll out new IPOs during the summer months, biotech companies have successfully captured investor interest. The sector has risen to a market-leading position by demonstrating stronger performance compared to AI firms. This highlights that innovations in biotechnology and drug development processes are increasingly valued by investors. Bankers indicate that biotech IPOs will continue through the summer, shaping market dynamics. AI listings, in contrast, have underperformed relative to biotech, taking a backseat. This is not investment advice.

📊 AMGN — Piyasa Yorumu

■ neutral · 60%

AMGN is currently trading at $364.11, up 1.5% over the past 24 hours, with the RSI at 48 indicating neutral momentum. The MACD remains below the signal line, and the stock has failed to achieve a sustained breakout above the SMA20 ($367.04). While the headline brings a positive tone to the biotechnology sector, it does not contain a direct catalyst for AMGN specifically. In the near term, sideways movement within the $362–$367 range is expected, with the SMA50 ($362.34) serving as a key support level to watch.

RSI 14

48.0

MACD

0.56

24h Δ

1.52%

📊 BIIB — Piyasa Yorumu

■ neutral · 60%

Although the news headline signals positive interest in the biotechnology sector, it does not contain a direct catalyst for BIIB stock. Technical indicators show the stock trading below its 20- and 50-day moving averages, with the RSI at 40.9 in neutral territory. The MACD remains below the signal line, indicating weak short-term momentum. Despite a 1.43% gain in the last 24 hours, the overall technical structure does not provide sufficient strength to determine a clear direction. Therefore, a sideways trend can be expected in the near term.

RSI 14

40.9

MACD

0.03

24h Δ

1.43%

Canlı Grafikler